Oncology dominates a 'Cambrian explosion' in China's drug pipeline as McKinsey guru bets on a burst of innovation
As the first wave of China’s homegrown new medicines begins to reach the market — from Chi-Med’s fruquintinib to Junshi’s toripalimab — they have also appeared to set the scene for the domination of oncology drugs in the biopharma pipeline.
In a post capturing Chinese biopharma’s “Cambrian Explosion” — a reference to the geological time period that marked a dramatic burst of evolutionary changes in life on Earth, courtesy of WuXi AppTec’s Steve Yang — Frank Le Deu, head of China healthcare at McKinsey, highlighted a classic herd effect:
Basic subscription required
Unlock this story instantly and join 53,000+ biopharma pros reading Endpoints daily — and it's free.